by Gus Iversen
, Editor in Chief | June 21, 2021
Women's health leader Hologic has acquired Mobidiag Oy, an innovator in near-patient, acute care molecular diagnostic testing, for approximately $808 million.
Mobidiag provides near-patient, molecular diagnostic instruments and tests for acute care conditions including gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare-associated infections.
“Closing the acquisition of Mobidiag enables us to become a broader, more diversified global diagnostics leader,” said Jan Verstreken, group president, international at Hologic, in a statement. “Together, we can accelerate development and adoption of Mobidiag’s innovative products globally and drive Hologic’s growth.”
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
Mobidiag's Amplidiag and Novodiag testing platforms deliver results in 50 minutes to two hours. The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing. Multiplexing enables multiple pathogens to be identified in a single sample, streamlining workflows for laboratories and providing rapid results to physicians.
In January, Hologic acquired Biotheranostics Inc.
, a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million.
Also in January, the company acquired SOMATEX Medical Technologies
, a developer of biopsy site markers and localization technologies, for approximately $64 million.